- US-listed companies
- SELLAS Life Sciences Group, Inc.
- Income statement
SELLAS Life Sciences Group, Inc. (SLS) Income statement
Market cap
$552.77M
P/E ratio
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 2 | 9 | - | - | - | - | - | 2 | 8 | 1 | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | - | - | |||
| Cost of revenue | 1 | 1 | - | - | - | - | - | - | 0 | 0 | - | - |
| Research & development | - | - | - | - | 6 | 9 | 7 | 9 | 16 | - | - | - |
| Selling, general & administrative | - | - | - | - | 15 | 13 | 10 | 10 | 11 | 13 | 14 | 12 |
| Operating margin (%) | - | - | - | - | - | - | - | |||||
| Operating expenses | 36 | 62 | 34 | 32 | - | 31 | 20 | 19 | 33 | 43 | 38 | 32 |
| Operating income | -34 | -52 | -34 | -32 | -23 | - | - | -17 | -25 | -42 | -38 | -32 |
| Income before tax | -76 | -37 | -39 | -11 | - | - | - | -17 | -21 | -41 | - | - |
| Pretax margin (%) | -3,040.9 | -392.8 | - | - | - | - | - | -882.8 | -275.5 | -4,130.1 | - | - |
| Provision for income taxes | 1 | - | 0 | 0 | 0 | -1 | -0 | -0 | -0 | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | |||||
| Net income | -77 | -37 | -64 | -24 | -24 | -28 | -19 | -17 | -21 | -41 | -37 | -31 |
| Net income margin (%) | - | - | - | - | - | - | - | |||||
| Earnings per share | - | - | - | - | - | - | - | - | -1.34 | -2.13 | -1.34 | -0.5 |
| Diluted EPS | - | - | - | - | - | - | - | - | -1.34 | -2.13 | -1.34 | -0.5 |
| EBITDA | - | - | - | - | - | - | - | - | ||||
| EBITDA margin (%) | - | - | - | - | - | - | - | - | - | - |